Device Trial Radar · NCT05413304
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5
Actual
Start
Apr 7, 2023
Primary completion
Oct 21, 2025
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jun 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults. Most people with these tumors survive less than 2 years. Researchers want to see if an anticancer drug (abemaciclib) can help. Objective: To see if researchers can measure how much abemaciclib is in a person's brain tumor and brain fluid after they take the drug for a few days. Eligibility: People aged 18 to 39 with recurrent high-grade glioma or diffuse midline glioma. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Tests of heart function Imaging scans of the brain, with a contrast agent Screening tests will be repeated during the study. Participants will also have chest X-rays. Participants will take abemaciclib by mouth twice a day for 4 and a half days. Participants will undergo surgery. They will have either a tumor biopsy (a needle will be inserted to remove a small piece of tissue) or a surgical resection (part or all of the tumor will be removed). A small tube (catheter) will be placed in their brain for 48 hours to collect fluid samples. They will have a neurological exam every few hours while the tube is in place. Two days later, the tube will be removed without surgery. Participants will stay in the hospital for about 4 days for treatment. Based on the results of abemaciclib levels in the brain, participants may keep taking abemaciclib and another drug (temozolomide) by mouth until their cancer gets worse or they have bad side effects. While taking these two drugs, participants will come back to the clinic for follow-up routinely. They will be followed by the study for life....
Conditions
- Glioma
Interventions
Pre-operative abemaciclibDrug
Pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
Device for Cerebral Fluid Dialysate CollectionDevice
Post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48 hours to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib
Ashion Analytics GEM ExTraDevice
Resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
abemaciclib + temozolomideDrug
Abemaciclib 150mg by mouth (po) twice a day (BID) and temozolomide 200mg/m\^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m\^2 po daily x 5 days for cycle 1)
TemozolomideDrug
Temozolomide 150mg/m\^2 by mouth (po) daily x 5 days for cycle 1
Brain MRIDiagnostic test
Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), as clinically indicated at catheter removal Day 7 (\>48 hours post op), maintenance therapy (after every 3 cycles), and post treatment (safety and long-term follow-up) as clinically indicated.
Brain CTDiagnostic test
Microdialysis (catheter in place) Day 5 and Day 6, and as clinically indicated at catheter removal Day 7 (\>48 hours post op).
EKGDiagnostic test
Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (\>48 hours post op).
Chest X-rayDiagnostic test
Baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (\>48 hours post op).
Biopsy/resectionProcedure
Microdialysis (catheter in place) Day 5 and Day 6.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence IntervalTime frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
- Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence IntervalTime frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
- Number of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving AbemaciclibTime frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.